Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Clinical Oncology

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2009.22.0616PMID 19738122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Multidisciplinary management of brain metastases].

  2010cited by this paper
• Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.

  2008cited by this paper
• Systemic therapy for lung cancer brain metastases: a rationale for clinical trials.

  2008cited by this paper
• Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy

  2008cited by this paper
• Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer

  2008cited by this paper
• What is the risk of intracranial bleeding during anti-VEGF therapy?

  2008cited by this paper
• Multidisciplinary management of brain metastases.

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006influential reference
• Current management of brain metastases, with a focus on systemic options.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.

  2005cited by this paper
• Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group.

  2005cited by this paper
• Management of brain metastases.

  2004cited by this paper
• Intracerebral haemorrhage secondary to metastasis from presumed non‐small cell lung carcinoma

  2004cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

  2004cited by this paper
• Treatment of brain metastases.

  2004cited by this paper
• The management of brain metastases.

  2003cited by this paper
• Spontaneous haemorrhage into metastatic brain tumours after stereotactic radiosurgery using a linear accelerator

  2003cited by this paper
• Management of brain metastases.

  1999cited by this paper
• Management of single brain metastasis: a practice guideline

  1997cited by this paper
• [Intracranial hemorrhage caused by metastatic tumors].

  1985cited by this paper
• Cerebral neoplasms initially presenting with massive intracerebral hemorrhage.

  1984cited by this paper
• Neoplastic aneurysm and intracranial hemorrhage

  1982cited by this paper
• Intracranial hemorrhage caused by metastatic tumors

  1977cited by this paper

• Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review

  2025cites this paper
• Emerging pharmacotherapies for brain metastases: a spotlight on angiogenesis inhibitors

  2025cites this paper
• Advances in molecular pathology and therapy of non-small cell lung cancer

  2025cites this paper
• Silica nanoparticles for brain cancer

  2023cites this paper
• Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability.

  2023cites this paper
• Where Are We Now and Where Might We Be Headed in Understanding and Managing Brain Metastases in Colorectal Cancer Patients?

  2022cites this paper
• A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation

  2022cites this paper
• Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer

  2022cites this paper
• Brain metastasis from colorectal cancer: Treatment, survival, and prognosis

  2022cites this paper
• Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

  2022cites this paper
• Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study

  2021cites this paper
• Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies

  2021cites this paper
• Stereotactic radiosurgery with whole brain radiotherapy combined with bevacizumab in the treatment of brain metastases from NSCLC

  2021cites this paper
• Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

  2021cites this paper
• Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis

  2021cites this paper
• Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study

  2021cites this paper
• Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

  2021cites this paper
• Rapid Growth of Anterior Chamber Metastasis From Presumed Non-Small Cell Lung Cancer During Targeted Therapy, Responding to a Single Intracameral Injection of Anti-Vascular Endothelial-Derived Growth Factor.

  2021cites this paper
• A systematic review and meta-analysis

  2021cites this paper
• Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases

  2021cites this paper
• Supportive Medical Management of Brain Metastases Patients Including Treatment Complications

  2020cites this paper
• Systemic treatment of brain metastases in non-small cell lung cancer.

  2020cites this paper
• Bevacizumab for non-small cell lung cancer patients with brain metastasis: A meta-analysis

  2020cites this paper
• СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О КОМБИНАЦИИ ЛУЧЕВОЙ ТЕРАПИИ С АНТИАНГИОГЕННЫМИ ПРЕПАРАТАМИ В ЛЕЧЕНИИ БОЛЬНЫХ С МЕТАСТАТИЧЕСКИМ ПОРАЖЕНИЕМ ГОЛОВНОГО МОЗГА

  2020cites this paper
• Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report

  2020cites this paper
• Integrating Systemic Therapy into the Management of Brain Metastases

  2020cites this paper
• Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

  2020cites this paper
• MODERN IDEAS ABOUT THE COMBINATION OF RADIATION THERAPY WITH ANTIANGIOGENIC DRUGS IN THE TREATMENT OF PATIENTS WITH BRAIN METASTASES

  2020cites this paper
• Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

  2020cites this paper
• Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment

  2019cites this paper
• Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.

  2019cites this paper
• Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis.

  2019cites this paper
• Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases

  2019cites this paper
• Antiangiogenics in Brain Metastases: Perspectives and Experiences

  2019cites this paper
• Anti-angiogenics in Brain Metastases: Perspectives and Experiences

  2019cites this paper
• Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.

  2019cites this paper
• Bevacizumab in Combination with Pemetrexed and Platinum Signi fi cantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases

  2019cites this paper
• Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases

  2019cites this paper
• Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

  2019cites this paper
• Long term Control of Metastatic Adenocarcinoma of the Lung to the Brain with Radiotherapy , Systemic Chemotherapy and Bevacizumab

  2019cites this paper
• Anti-angiogenic therapies in brain metastases

  2018cites this paper
• First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation.

  2018cites this paper
• A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

  2018cites this paper
• Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management

  2018cites this paper
• Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Neurological complications of lung cancer

  2018cites this paper
• Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer

  2018cites this paper
• Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2017cites this paper
• First-Line Systemic Therapy for Non-Small Cell Lung Cancer.

  2017cites this paper
• 中国肺癌脑转移诊治专家共识（2017年版）

  2017cites this paper
• Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.

  2017cites this paper
• 贝伐珠单抗在非小细胞肺癌中的应用进展

  2017cites this paper
• Thérapies moléculaires ciblées en cancérologie pulmonaire

  2017cites this paper
• Leptomeningeal disease: current diagnostic and therapeutic strategies

  2017cites this paper
• Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy

  2017cites this paper
• Brain metastases from non-small cell lung carcinoma: Changing concepts for improving patients' outcome.

  2017cites this paper
• Systemic Treatment of Brain Metastases.

  2017cites this paper
• Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

  2017cites this paper
• Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis

  2017cites this paper
• Bevacizumab Plus Radiosurgery for Nonsquamous Non-Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?

  2017cites this paper
• Bevacizumab in advanced lung cancer: state of the art.

  2017cites this paper
• Bevacizumab in the treatment of NSCLC: patient selection and perspectives

  2017cites this paper
• Treatment of brain metastases of lung cancer in the era of precision medicine.

  2016cites this paper
• Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer

  2016cites this paper
• Place des antiangiogéniques dans le traitement des cancers du poumon

  2016cites this paper
• Brain metastases from non-small cell lung cancer : radiation therapy in the era of targeted therapies

  2016cites this paper
• Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases

  2016cites this paper
• 贝伐珠单抗治疗非小细胞肺癌脑转移的研究进展

  2016cites this paper
• Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies

  2016cites this paper
• Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors

  2016cites this paper
• Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

  2016cites this paper
• Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

  2016cites this paper
• A dynamic in vivo-like organotypic blood-brain barrier model to probe metastatic brain tumors

  2016cites this paper
• Retrospective analysis of bevacizumab‐induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer

  2016cites this paper
• A Case of Cecal Cancer Presented with Solitary Brain Metastasis

  2016cites this paper
• Systemic Immunotherapy for the Treatment of Brain Metastases

  2016cites this paper
• Systemic therapies in the treatment of non-small-cell lung cancer brain metastases.

  2016cites this paper
• Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.

  2016influential citation
• Cases of Non-small Cell Lung Cancer with Brain Metastases Treated with Bevacizumab in Our Hospital

  2016cites this paper
• Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases.

  2016cites this paper
• Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm.

  2016cites this paper
• Systemic treatment of non-small cell lung cancer brain metastases

  2016cites this paper
• Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis

  2016cites this paper
• The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update

  2015cites this paper
• Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis

  2015cites this paper
• Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non-Small-Cell Lung Cancer with Brain Metastases.

  2015cites this paper
• Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results

  2015cites this paper
• Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non‐small‐cell lung cancer: A meta‐analysis of 15 phase II/III randomized trials

  2015cites this paper
• Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis

  2015cites this paper
• Treatment of Brain Metastases.

  2015cites this paper
• Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer

  2015cites this paper
• Antiangiogéniques en cancérologie thoracique : critères de prescription et gestion des effets indésirables

  2015cites this paper
• Therapy options for advanced NSCLC

  2015cites this paper
• Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.

  2015cites this paper
• REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours.

  2014cites this paper
• The role of systemic and targeted therapies in brain metastases

  2014cites this paper
• Bevacizumab for critical brain metastases in a patient with pulmonary pleomorphic carcinoma.

  2014influential citation
• Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update

  2014cites this paper
• Anti‐Angiogenic Agents in Metastatic NSCLC

  2014cites this paper